Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Celgene Corporation

Share:
Related CELG
Your Cheat Sheet For Q1 Biotech Earnings
Leerink Presents: Your 2017 Biopharma Catalyst Tracker
Tech, Industrial Giants To Report As Euro Rallies: Investing Action Plan (Investor's Business Daily)

In a report published Monday, Jefferies & Company reiterated its Buy rating on Celgene Corporation (NASDAQ: CELG), and raised its price target from $91.00 to $94.00.

Jefferies noted, “CELG announced Abraxane met its overall survival primary endpoint in its Phase 3 pancreatic cancer study. We have long considered this indication to be risky and upside to our valuation. Adding pancreatic cancer to our valuation raises our price target from $91 to $94.”

Celgene Corporation closed on Friday at $71.50.

Latest Ratings for CELG

DateFirmActionFromTo
Nov 2016OppenheimerInitiates Coverage OnOutperform
Nov 2016Standpoint ResearchDowngradesBuyHold
Nov 2016MizuhoInitiates Coverage OnBuy

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (CELG)

View Comments and Join the Discussion!